Antiviral Drugs Market To Reach USD 71.48 Billion By 2026 | Reports And Data
August 26, 2019 12:14 ET
|
Reports and Data
New York, Aug. 26, 2019 (GLOBE NEWSWIRE) -- Factors attributed to the growing CAGR and high demand for the antiviral drugs market are higher incidences of HIV and other life-threatening diseases...
Vaccines Market value to hit $72.5 billion by 2025: Global Market Insights, Inc.
August 15, 2019 02:30 ET
|
Global Market Insights, Inc
Selbyville, Delaware, Aug. 15, 2019 (GLOBE NEWSWIRE) -- Global Market Insights, Inc., announces a research report on ‘Vaccines Market Trends and Forecast 2019-2025’. The report covers an extensive...
Vaccines Market worth over $70bn by 2025: Global Market Insights, Inc.
March 07, 2019 06:00 ET
|
Global Market Insights, Inc
Selbyville, Delaware, March 07, 2019 (GLOBE NEWSWIRE) -- The vaccines market is estimated to hike from over USD 38 billion in 2018 to over USD 70 billion by 2025, according to a 2019 Global Market...
PEGylated Drugs Market in Europe and North America worth over $10.5 billion by 2024: Global Market Insights, Inc.
April 17, 2018 04:00 ET
|
Global Market Insights, Inc
Sellbyville, Delaware, April 17, 2018 (GLOBE NEWSWIRE) -- North America and Europe PEGylated Drugs Market is expected to surpass USD 10.5 billion by 2024; according to a new research report by...
New Pathogen-Detection Technology Identifies Infectious Diseases
May 26, 2016 13:51 ET
|
ARUP Laboratories
SALT LAKE CITY, May 26, 2016 (GLOBE NEWSWIRE) -- ARUP Laboratories Medical Director Robert Schlaberg, MD, Dr Med, MPH, will be the Principal Investigator for a project to help decrease the high...
OnCore Biopharma Licenses Second-Generation Cyclophilin Inhibitors From NeuroVive for the Treatment of Chronic HBV Infection
September 09, 2014 03:00 ET
|
OnCore Biopharma, Inc.
OnCore Secures Exclusive Worldwide Rights to NVP018
NVP018 Will Complement OnCore's Existing Pipeline Directed at Achieving All-Oral Cure for HBV
DOYLESTOWN, Pa., Sept. 9, 2014 (GLOBE NEWSWIRE)...
OnCore Biopharma Closes Series R Financing
September 05, 2014 07:00 ET
|
OnCore Biopharma, Inc.
Funds to Expand OnCore's Portfolio of Oral Therapeutics for the Treatment of Chronic HBV
OnCore to Advance HBV Compounds Into Phase 1 Clinical Development During 2015
Former Pharmasset Team...
Hemispherx Biopharma Gains Broad Treatment Expansion for Alferon N Injection(R) in Argentina
March 04, 2013 08:00 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, March 4, 2013 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), announced that ANMAT (Administracion Nacional de Medicamentos, Alimentos y...
International Patent Application Submitted Covering Vaccines for Influenza (Universal Vaccine), Hepatitis C, Cytomegalovirus and Human Papillomavirus
June 07, 2012 07:00 ET
|
Bionor Pharma
OSLO, NORWAY--(Marketwire - Jun 7, 2012) - Bionor Pharma ASA (OSLO: BIONOR)
News Summary
The new patent filed 6 June aims to strengthen the Company's general protection of its...
Immunitor Completes Phase IIb imm01 Trial Enrollment and Plans Further Trials of V5
November 14, 2010 23:21 ET
|
Immune Network Ltd
VANCOUVER, British Columbia, Nov. 14, 2010 (GLOBE NEWSWIRE) -- Immune Network Ltd. (Pink Sheets:IMMFF), advises that its potential acquisition, Immunitor USA Inc., has announced the completion of...